Daily Market Reports | Apr 09 2026
This story features AIC MINES LIMITED, and other companies.
For more info SHARE ANALYSIS: A1M
The company is included in ALL-ORDS
An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities.
In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Australian Broker Call *Extra* Edition, featuring additional sources of research and insights on ASX-listed stocks, also enlarging the number of stocks that make up the FNArena universe.
One key difference is the *Extra* Edition will not be updated daily, but merely “regularly” depending on availability of suitable quality content. As such, the *Extra* Edition tries to build a bridge between daily updates via the Australian Broker Call Report and ad hoc news stories, that are not always timely for investors hungry for the next information update.
Investors using the *Extra* Edition as a source of input for their own share market research should thus take into account that information after publication may not be up to date, or yet awaiting another update by FNArena’s team of journalists.
Similar to The Australian Broker Call Report, this *Extra* Edition includes concise but limited reviews of research recently published by Stockbrokers and other experts, which should be considered as information concerning likely market behaviour rather than advice on the securities mentioned. Do not act on the contents of this Report without first reading the important information included at the end of this Report.
The Australian Broker Call *Extra* Edition is a summary that has been prepared independently of the sources identified. Readers will check the full text of the recommendations and consult a Licenced Advisor before making any investment decision.
The copyright of this Report is owned by the publisher. Readers will not copy, forward or disseminate this Report to any other person. For more vital information about the sources included, see the bottom of this Report.
COMPANIES DISCUSSED IN THIS ISSUE
Click on a symbol for fast access.
The number next to the symbol represents the number of brokers covering it for this report -(if more than 1)
A1M ALK APE ARB BOQ CBA CGS CU6 GL1 GYG LOT MQG PLY RMS SGQ TLX (2) TOR WC8 (2)
A1M AIC MINES LIMITED
Gold & Silver – Overnight Price: $0.58
Shaw and Partners rates ((A1M)) as Buy (1) –
AIC Mines has reported record growth at Eloise and Jericho, which significantly increases copper resources and reserves while advancing key infrastructure, Shaw and Partners notes.
Combined mineral resources for the Eloise project have increased by 10% with 31.2mt containing 631,800t copper. Combined ore reserves increased 40% to 10.2mt, containing 191,000t copper.
Resources at Jericho increased by 15% to 22.1mt with contained copper rising 17% to 444,900t. Growth was driven by the discovery of the new JO lens and extension of the J1 mineral sources by 600m along strike.
The broker retains a Buy, High Risk rating and target of $1.10.
This report was published on April 7, 2026.
Target price is $1.10 Current Price is $0.58 Difference: $0.515
If A1M meets the Shaw and Partners target it will return approximately 88% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Shaw and Partners forecasts a full year FY26 dividend of 0.00 cents and EPS of 8.30 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 7.05.
Forecast for FY27:
Shaw and Partners forecasts a full year FY27 dividend of 0.00 cents and EPS of 17.10 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 3.42.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
ALK ALKANE RESOURCES LIMITED
Gold & Silver – Overnight Price: $1.72
Moelis rates ((ALK)) as Buy (1) –
Alkane Resources has provided early production numbers for the March quarter, which Moelis finds were slightly ahead of forecasts owing to better production at Bjorkdal.
The probability is higher realised prices for gold and antimony have contributed to a higher cash balance relative to forecasts. The company has reiterated FY26 guidance for 160-175,000 ounces of gold equivalent.
This suggests to the broker confidence in the rest of the financial year, with only 37,000 ounces of gold required in the fourth quarter to meet the lower end of production guidance
Moelis also suggests the merger with Mandalay may, if performance is consistent, help endear the company to new investors. Buy rating and $2.25 target.
This report was published on April 9, 2026.
Target price is $2.25 Current Price is $1.72 Difference: $0.53
If ALK meets the Moelis target it will return approximately 31% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Moelis forecasts a full year FY26 dividend of 0.00 cents and EPS of 16.78 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 10.25.
Forecast for FY27:
Moelis forecasts a full year FY27 dividend of 0.00 cents and EPS of 27.08 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 6.35.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
APE EAGERS AUTOMOTIVE LIMITED
Automobiles & Components – Overnight Price: $24.00
Canaccord Genuity rates ((APE)) as Buy (1) –
Canaccord Genuity maintains a Buy rating and 32.00 target for Eagers Automotive following March 2026 new vehicle sales data showing a -2.6% decline on the year prior.
The broker highlights lower headline numbers are primarily supply-driven by constraints at Toyota, with underlying demand across major models remaining above current sales levels.
BYD recorded near-record sales and order write, benefiting from high fuel prices and growing EV interest, with the upcoming Denza brand launch providing further upside.
Canaccord Genuity expects a weighted 2H26 earnings bias following the close of the CanadaOne acquisition and views the medium-term thesis as anchored in further expansion activity.
This report was published on April 7, 2026.
Target price is $32.00 Current Price is $24.00 Difference: $8
If APE meets the Canaccord Genuity target it will return approximately 33% (excluding dividends, fees and charges).
Current consensus price target is $30.43, suggesting upside of 31.1%(ex-dividends)
Forecast for FY26:
Current consensus EPS estimate is 120.8, implying annual growth of 38.7%.
Current consensus DPS estimate is 85.5, implying a prospective dividend yield of 3.7%.
Current consensus EPS estimate suggests the PER is 19.2.
Forecast for FY27:
Current consensus EPS estimate is 135.3, implying annual growth of 12.0%.
Current consensus DPS estimate is 91.0, implying a prospective dividend yield of 3.9%.
Current consensus EPS estimate suggests the PER is 17.2.
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
ARB ARB CORPORATION LIMITED
Automobiles & Components – Overnight Price: $21.35
Canaccord Genuity rates ((ARB)) as Hold (3) –
Canaccord Genuity maintains a Hold rating on ARB Corp by Andrew Hodge and Arina Chong with a $22.90 price target following March 2026 vehicle sales data.
The Top 11 index declined 7.8% year-on-year, marking another negative month after a brief stabilisation, with weakness partly reflecting prior period strength in key models like the Toyota Prado.
Manufacturers are managing supply and inventory to meet New Vehicle Efficiency Standard (NVES) requirements, commentary highlights, which is also impacting volumes for major 4WD models.
The broker sees downside risk to FY27 forecasts, with valuation reflecting potential earnings revisions in a softer demand environment.
This report was published on April 7, 2026.
Target price is $22.90 Current Price is $21.35 Difference: $1.55
If ARB meets the Canaccord Genuity target it will return approximately 7% (excluding dividends, fees and charges).
Current consensus price target is $28.06, suggesting upside of 35.5%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.00 cents.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 106.4, implying annual growth of -9.6%.
Current consensus DPS estimate is 70.8, implying a prospective dividend yield of 3.4%.
Current consensus EPS estimate suggests the PER is 19.5.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 0.00 cents.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 119.3, implying annual growth of 12.1%.
Current consensus DPS estimate is 72.5, implying a prospective dividend yield of 3.5%.
Current consensus EPS estimate suggests the PER is 17.4.
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
BOQ BANK OF QUEENSLAND LIMITED
Banks – Overnight Price: $7.22
Jarden rates ((BOQ)) as Sell (5) –
Jarden maintains a Sell rating on Bank of Queensland, with $6.00 price target, following the announced sale of $3.7bn in equipment finance assets.
The broker views the transaction as a repeat of the unsustainable financial engineering strategy seen from 2001 to 2007, where growth was prioritised through leverage at the expense of the core franchise.
While the sale facilitates a $300m capital return to shareholders and provides a minor boost to Return on Equity (RoE), the report highlights it results in a -$31m post-tax loss and structural impairment of revenue.
The originate-to-sell model is seen as a short-term funding arbitrage that lacks sustainable franchise value, particularly as the regional lender continues to lose market share in its core home loan business.
This report was published on April 7, 2026.
Target price is $6.00 Current Price is $7.22 Difference: minus $1.22 (current price is over target).
If BOQ meets the Jarden target it will return approximately minus 17% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $6.82, suggesting downside of -8.7%(ex-dividends)
The company’s fiscal year ends in August.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.00 cents.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 57.5, implying annual growth of 184.5%.
Current consensus DPS estimate is 48.2, implying a prospective dividend yield of 6.5%.
Current consensus EPS estimate suggests the PER is 13.0.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 0.00 cents and EPS of 0.00 cents.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 61.1, implying annual growth of 6.3%.
Current consensus DPS estimate is 40.8, implying a prospective dividend yield of 5.5%.
Current consensus EPS estimate suggests the PER is 12.2.
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
CBA COMMONWEALTH BANK OF AUSTRALIA
Banks – Overnight Price: $180.21
Jarden rates ((CBA)) as Sell (5) –
The RBA has rejected submissions from CommBank, National Australia Bank ((NAB)) and Westpac ((WBC)), proceeding instead with its preferred reforms.
The broker explains these reforms involve the removal of surcharging, lowering interchange fees to reduce cross-subsidisation between credit and debit cards, and improving transparency around card payment fees.
The analysts explain the abolition of card surcharging and changes to interchange fees will take effect from October 1, 2026, aligning Australia with regulatory settings in the EU and UK.
The debit interchange cap has also been reduced to 8c from 10c, representing a more favourable outcome than the initially proposed 6c.
Jarden has an unchanged Sell rating and $90 target for CommBank.
This report was published on March 31, 2026.
Target price is $90.00 Current Price is $180.21 Difference: minus $90.21 (current price is over target).
If CBA meets the Jarden target it will return approximately minus 50% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $127.58, suggesting downside of -29.9%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 505.00 cents and EPS of 634.00 cents.
At the last closing share price the estimated dividend yield is 2.80%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 28.42.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 656.4, implying annual growth of 8.5%.
Current consensus DPS estimate is 505.0, implying a prospective dividend yield of 2.8%.
Current consensus EPS estimate suggests the PER is 27.7.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 520.00 cents and EPS of 610.00 cents.
At the last closing share price the estimated dividend yield is 2.89%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 29.54.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 689.4, implying annual growth of 5.0%.
Current consensus DPS estimate is 531.0, implying a prospective dividend yield of 2.9%.
Current consensus EPS estimate suggests the PER is 26.4.
Market Sentiment: -1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
CGS COGSTATE LIMITED
Medical Equipment & Devices – Overnight Price: $2.40
Canaccord Genuity rates ((CGS)) as Buy (1) –
Canaccord Genuity maintains a Buy rating on Cogstate with $3.15 price target following a third quarter FY26 trading update.
Total sales orders and contracted revenue for FY26 are tracking in line with full-year forecasts, supporting earnings visibility.
The broker highlights expanding opportunities beyond Alzheimer’s into mood, sleep and rare diseases, which are contributing an increasing share of sales.
Earnings leverage is expected over the forecast period, with future valuation supported by continued growth across the pipeline.
This report was published on April 8, 2026.
Target price is $3.15 Current Price is $2.40 Difference: $0.75
If CGS meets the Canaccord Genuity target it will return approximately 31% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 10.56 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 22.74.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 12.06 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 19.90.
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
CU6 CLARITY PHARMACEUTICALS LIMITED
Medical Equipment & Devices – Overnight Price: $3.25
Canaccord Genuity rates ((CU6)) as Buy (1) –
Canaccord Genuity maintains a Buy rating on Clarity Pharmaceuticals with a $8.41 price target after lowering it from $9.00 due to FX and timeline adjustments.
The broker highlights the upcoming Phase III diagnostic trials Clarify and Cobra-Kai as key milestones for the company’s prostate cancer imaging agent.
Commentary explains Clarity’s platform is distinguished by its use of copper for both imaging and therapy, which simplifies logistics compared to traditional radiopharmaceuticals.
Future valuation is supported by the therapeutic pipeline, despite the nearer-term commercial potential of the diagnostic products, the report concludes.
This report was published on April 8, 2026.
Target price is $8.41 Current Price is $3.25 Difference: $5.16
If CU6 meets the Canaccord Genuity target it will return approximately 159% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.00 cents.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 0.00 cents.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
GL1 GLOBAL LITHIUM RESOURCES LIMITED
New Battery Elements – Overnight Price: $0.50
Shaw and Partners rates ((GL1)) as Reinstate Coverage with Buy (1) –
Shaw and Partners reinstates coverage of Global Lithium Resources with a Buy rating and $1.50 target. The broker observes the company is rapidly moving its Manna lithium project into production having secured native title and a mining lease.
The project is considered a “premier” asset of world-class ranking, being the third-largest hard rock lithium resource in the eastern goldfields.
The broker also points out the project is underpinned by major industry operators such as Mineral Resources ((MIN)) which holds a 9.9% strategic stake, while the assets are located close to the world-class Wodgina and Mount Marion mines.
Shaw and Partners expects a supply deficit in the lithium market by the end of 2026 of -20k-80k metric tonnes.
This report was published on April 8, 2026.
Target price is $1.50 Current Price is $0.50 Difference: $1
If GL1 meets the Shaw and Partners target it will return approximately 200% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Shaw and Partners forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 1.50 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 33.33.
Forecast for FY27:
Shaw and Partners forecasts a full year FY27 dividend of 0.00 cents and EPS of minus 4.60 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 10.87.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
GYG GUZMAN Y GOMEZ LIMITED
Food, Beverages & Tobacco – Overnight Price: $20.25
Jarden rates ((GYG)) as Neutral (3) –
Jarden maintains a Neutral rating on Guzman y Gomez with a $17.30 price target following a strong 3Q FY26 trading update.
The report highlights Australian like-for-like sales rose 6.6%, accelerating to approximately 9% in the final weeks of the quarter, driven by volume growth from the UberEats partnership and value promotions.
While Australian EBITDA margins remain within guidance, the broker retains a Neutral stance due to expected macro and cost headwinds, including rising competition and consumer pressure.
The target price was increased from $17.10 to reflect the stronger top-line performance, although store roll-out targets and offshore challenges in the US remain points of caution.
This report was published on April 7, 2026.
Target price is $17.30 Current Price is $20.25 Difference: minus $2.95 (current price is over target).
If GYG meets the Jarden target it will return approximately minus 15% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $25.01, suggesting upside of 23.6%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 5.00 cents and EPS of 17.70 cents.
At the last closing share price the estimated dividend yield is 0.25%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 114.41.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 20.0, implying annual growth of 40.3%.
Current consensus DPS estimate is 12.2, implying a prospective dividend yield of 0.6%.
Current consensus EPS estimate suggests the PER is 101.2.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 24.00 cents and EPS of 36.20 cents.
At the last closing share price the estimated dividend yield is 1.19%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 55.94.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 35.8, implying annual growth of 79.0%.
Current consensus DPS estimate is 21.6, implying a prospective dividend yield of 1.1%.
Current consensus EPS estimate suggests the PER is 56.5.
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
LOT LOTUS RESOURCES LIMITED
Uranium – Overnight Price: $1.49
Canaccord Genuity rates ((LOT)) as Buy (1) –
Canaccord Genuity maintains a Speculative Buy rating on Lotus Resources with a $3.10 price target following a fire in the drying and packaging area of the Kayelekera Uranium Mine.
The incident has resulted in a three-week suspension of processing, prompting the broker to lower near-term production forecasts and increase operating cost assumptions.
While commissioning of the new acid plant is deferred until production resumes, the facility is expected to eventually streamline logistics and eliminate costly sulphuric acid imports.
The broker continues to view steady-state production of approximately 200,000 lbs per month as achievable by the June quarter of 2026.
This report was published on April 8, 2026.
Target price is $3.10 Current Price is $1.49 Difference: $1.615
If LOT meets the Canaccord Genuity target it will return approximately 109% (excluding dividends, fees and charges).
Current consensus price target is $3.45, suggesting upside of 139.6%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 27.40 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 5.42.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is -17.4, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is N/A.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 5.10 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 29.12.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 13.2, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 10.9.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
MQG MACQUARIE GROUP LIMITED
Wealth Management & Investments – Overnight Price: $224.10
Jarden rates ((MQG)) as Buy (1) –
Australian private sector credit growth was 7.8% year-on-year in February 2026, and business credit growth remained strong, rising by 9.5%, observes Jarden.
The broker notes Macquarie Group continues to outperform the major banks, supported by a superior, fully digitised platform.
At the current pace, the group is expected to surpass around 10% market share on both sides of the balance sheet in the near term.
Jarden retains a Buy rating and $240 target for Macquarie Group.
This report was published on March 31, 2026.
Target price is $240.00 Current Price is $224.10 Difference: $15.9
If MQG meets the Jarden target it will return approximately 7% (excluding dividends, fees and charges).
Current consensus price target is $229.30, suggesting upside of 2.7%(ex-dividends)
The company’s fiscal year ends in March.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 700.00 cents and EPS of 1091.40 cents.
At the last closing share price the estimated dividend yield is 3.12%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 20.53.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 1127.4, implying annual growth of 15.1%.
Current consensus DPS estimate is 718.5, implying a prospective dividend yield of 3.2%.
Current consensus EPS estimate suggests the PER is 19.8.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 830.00 cents and EPS of 1296.40 cents.
At the last closing share price the estimated dividend yield is 3.70%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 17.29.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 1195.1, implying annual growth of 6.0%.
Current consensus DPS estimate is 773.5, implying a prospective dividend yield of 3.5%.
Current consensus EPS estimate suggests the PER is 18.7.
Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
PLY PLAYSIDE STUDIOS LIMITED
Gaming – Overnight Price: $0.27
Shaw and Partners rates ((PLY)) as Buy (1) –
Playside Studios will launch Mouse: P.I. For Hire on April 16.
Shaw and Partners highlights review count is the best “post-launch metric to track” and envisages a unique opportunity in the company which has invested substantially in its original IP portfolio over the last 18 months.
The broker continues to believe this will be a major revenue generator and reiterates its Buy rating. Target is $0.44.
This report was published on April 9, 2026.
Target price is $0.44 Current Price is $0.27 Difference: $0.175
If PLY meets the Shaw and Partners target it will return approximately 66% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Shaw and Partners forecasts a full year FY26 dividend of 0.00 cents and EPS of 2.80 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 9.46.
Forecast for FY27:
Shaw and Partners forecasts a full year FY27 dividend of 0.00 cents and EPS of 2.60 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 10.19.
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
RMS RAMELIUS RESOURCES LIMITED
Gold & Silver – Overnight Price: $4.10
Shaw and Partners rates ((RMS)) as Buy (1) –
Ramelius Resources delivered preliminary March quarter production results revealing 38,100 ounces.
Shaw and Partners points out March production continues to show sequentially falling FY26 production. The quarter was affected by a planned 6-day plant shutdown and high rainfall associated with Cyclone Narelle.
The delays have also bolstered the high-grade stockpiles which the company expects will contribute to a stronger fourth quarter as will a return to high-grade mining at the Cue pits.
FY26 production is expected around the midpoint of guidance of 18.5k-205k ounces.
The broker transfers coverage of Ramelius Resources to Alex Barkley. Buy rating and $6.50 target retained.
This report was published on April 9, 2026.
Target price is $6.50 Current Price is $4.10 Difference: $2.4
If RMS meets the Shaw and Partners target it will return approximately 59% (excluding dividends, fees and charges).
Current consensus price target is $5.29, suggesting upside of 31.3%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Shaw and Partners forecasts a full year FY26 dividend of 5.00 cents and EPS of 23.40 cents.
At the last closing share price the estimated dividend yield is 1.22%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 17.52.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 17.7, implying annual growth of -57.0%.
Current consensus DPS estimate is 4.5, implying a prospective dividend yield of 1.1%.
Current consensus EPS estimate suggests the PER is 22.8.
Forecast for FY27:
Shaw and Partners forecasts a full year FY27 dividend of 10.50 cents and EPS of 46.90 cents.
At the last closing share price the estimated dividend yield is 2.56%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 8.74.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 31.0, implying annual growth of 75.1%.
Current consensus DPS estimate is 5.9, implying a prospective dividend yield of 1.5%.
Current consensus EPS estimate suggests the PER is 13.0.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
SGQ ST. GEORGE MINING LIMITED
Rare Earth Minerals – Overnight Price: $0.13
Canaccord Genuity rates ((SGQ)) as Speculative Buy (1) –
Canaccord Genuity maintains a Speculative Buy rating on St George Mining with a $0.23 price target following the reporting of record drill intercepts at the Araxa Project in Brazil.
The latest results included a standout intercept of 178.7m at 4.34% TREO and 0.75% Nb2O5 from surface, representing the thickest mineralised interval recorded at the project to date.
The broker views these results as supporting the potential for Araxa to become a globally significant resource for rare earths and niobium.
Key upcoming catalysts for 2026 include metallurgical test work results in the June quarter, an economic study, and an updated Mineral Resource Estimate in the September quarter.
Strategic partnerships and MOUs with Boston Metal and Tecnicas Reunidas are also seen as positive steps in de-risking the project’s development.
This report was published on April 7, 2026.
Target price is $0.23 Current Price is $0.13 Difference: $0.1
If SGQ meets the Canaccord Genuity target it will return approximately 77% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.00 cents.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 0.00 cents.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
TLX TELIX PHARMACEUTICALS LIMITED
Pharmaceuticals & Biotech/Lifesciences – Overnight Price: $13.95
Canaccord Genuity rates ((TLX)) as Buy (1) –
Canaccord Genuity maintains a Buy rating on Telix Pharmaceuticals with a $30.00 price target, raised from $28.50, following a significant sales ‘beat’ in the first quarter of 2026.
Total revenue of $230m exceeded the broker’s estimate by 9%, driven largely by a 14% outperformance in Illuccix sales which reached $186m.
Commentary highlights the company is successfully maintaining its market share in the PSMA-PET imaging space while preparing for the commercial launch of Zircaix.
Management has confirmed its full-year revenue guidance of $950m to $970m, underpinned by strong underlying demand and the execution of a two-product strategy.
This report was published on April 8, 2026.
Target price is $30.00 Current Price is $13.95 Difference: $16.05
If TLX meets the Canaccord Genuity target it will return approximately 115% (excluding dividends, fees and charges).
Current consensus price target is $25.84, suggesting upside of 91.0%(ex-dividends)
Forecast for FY26:
Current consensus EPS estimate is -3.4, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is N/A.
Forecast for FY27:
Current consensus EPS estimate is 31.3, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 43.2.
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
Jarden rates ((TLX)) as Buy (1) –
Jarden maintains a Buy rating on Telix Pharmaceuticals with a 21.80 price target following a strong first quarter FY26 trading update.
Revenue growth was driven by continued strength in the precision medicine segment, supporting momentum across the core portfolio.
Full-year revenue guidance of US$950m to US$970m is maintained, with potential upside from upcoming product launches.
While operating costs are expected to increase to support growth, commentary posits the company remains on track toward breakeven over the forecast period.
This report was published on April 7, 2026.
Target price is $21.80 Current Price is $13.95 Difference: $7.85
If TLX meets the Jarden target it will return approximately 56% (excluding dividends, fees and charges).
Current consensus price target is $25.84, suggesting upside of 91.0%(ex-dividends)
The company’s fiscal year ends in December.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.91 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 1541.44.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is -3.4, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is N/A.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 0.00 cents and EPS of 2.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 697.50.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 31.3, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 43.2.
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
TOR TORQUE METALS LIMITED
Gold & Silver – Overnight Price: $0.49
Canaccord Genuity rates ((TOR)) as Speculative Buy (1) –
Canaccord Genuity maintains a Speculative Buy rating with a $0.55 price target following strong drilling results at the Paris Gold Project.
High-grade intercepts including 5m at 15.24g/t Au and 12.59m at 12.47g/t Au reinforce mineralisation continuity and support potential for a larger system.
Drilling has extended mineralisation up to 500m beyond the current resource boundary, indicating significant scale upside, the report highlights.
Additional results at the nearby HHH deposit suggest further growth potential across the broader project.
Future value is tied to an updated Mineral Resource Estimate expected later this quarter, with the broker citing potential for the resource base to approach 800koz.
This report was published on April 8, 2026.
Target price is $0.55 Current Price is $0.49 Difference: $0.06
If TOR meets the Canaccord Genuity target it will return approximately 12% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.00 cents.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 0.00 cents.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
WC8 WILDCAT RESOURCES LIMITED
New Battery Elements – Overnight Price: $0.39
Canaccord Genuity rates ((WC8)) as Speculative Buy (1) –
Canaccord Genuity maintains a Speculative Buy rating with a $0.75 price target following promising drilling results at the Bolt Cutter lithium discovery.
Known mineralisation at the site has expanded to over 2.3km in strike length after exploration drilling extended the known stacked pegmatite mineralisation by 300m.
Results from the recent campaign returned aggregate widths of up to 15m at grades up to 2% Li2O, and the deposit remains open along strike and at depth.
The broker views Bolt Cutter as having significant potential for integration into the broader Tabba Tabba development plans, which could improve feed grades and mine life.
Inclusion of this near-surface mineralisation into the production model could provide high-grade feed to offset lower-grade resources at the main project area, the report suggests.
This report was published on April 7, 2026.
Target price is $0.75 Current Price is $0.39 Difference: $0.365
If WC8 meets the Canaccord Genuity target it will return approximately 95% (excluding dividends, fees and charges).
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
Shaw and Partners rates ((WC8)) as Buy (1) –
Wildcat Resources has extended the spodumene footprint of the Bolt Cutter discovery by 300m to the north.
Shaw and Partners notes current high fuel prices have created a “perfect storm” for electric vehicle demand which should tip the lithium market into deficit by the end of the year.
Results of drilling to date demonstrate potential for Bolt Cutter to grow in scale both laterally and depth and it is expected to be a key component of the company’s strategy of exploration and development.
First production is targeted for 2028. Buy retained. Target unchanged at $1.20.
This report was published on April 8, 2026.
Target price is $1.20 Current Price is $0.39 Difference: $0.815
If WC8 meets the Shaw and Partners target it will return approximately 212% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Shaw and Partners forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 0.90 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 42.78.
Forecast for FY27:
Shaw and Partners forecasts a full year FY27 dividend of 0.00 cents and EPS of minus 0.80 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 48.13.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
Disclaimer:
The content of this information does in no way reflect the opinions of FNArena, or of its journalists. In fact we don’t have any opinion about the stock market, its value, future direction or individual shares. FNArena solely reports about what the main experts in the market note, believe and comment on. By doing so we believe we provide experienced, intelligent investors with a valuable tool that helps them in making up their own minds, reading market trends and getting a feel for what is happening beneath the surface.
This document is provided for informational purposes only. It does not constitute an offer to sell or a solicitation to buy any security or other financial instrument. FNArena employs very experienced journalists who base their work on information believed to be reliable and accurate, though no guarantee is given that the daily report is accurate or complete. Investors should contact their personal adviser before making any investment decision.
<span style="
Click to view our Glossary of Financial Terms
CHARTS
For more info SHARE ANALYSIS: A1M - AIC MINES LIMITED
For more info SHARE ANALYSIS: ALK - ALKANE RESOURCES LIMITED
For more info SHARE ANALYSIS: APE - EAGERS AUTOMOTIVE LIMITED
For more info SHARE ANALYSIS: ARB - ARB CORPORATION LIMITED
For more info SHARE ANALYSIS: BOQ - BANK OF QUEENSLAND LIMITED
For more info SHARE ANALYSIS: CBA - COMMONWEALTH BANK OF AUSTRALIA
For more info SHARE ANALYSIS: CGS - COGSTATE LIMITED
For more info SHARE ANALYSIS: CU6 - CLARITY PHARMACEUTICALS LIMITED
For more info SHARE ANALYSIS: GL1 - GLOBAL LITHIUM RESOURCES LIMITED
For more info SHARE ANALYSIS: GYG - GUZMAN Y GOMEZ LIMITED
For more info SHARE ANALYSIS: LOT - LOTUS RESOURCES LIMITED
For more info SHARE ANALYSIS: MIN - MINERAL RESOURCES LIMITED
For more info SHARE ANALYSIS: MQG - MACQUARIE GROUP LIMITED
For more info SHARE ANALYSIS: NAB - NATIONAL AUSTRALIA BANK LIMITED
For more info SHARE ANALYSIS: PLY - PLAYSIDE STUDIOS LIMITED
For more info SHARE ANALYSIS: RMS - RAMELIUS RESOURCES LIMITED
For more info SHARE ANALYSIS: SGQ - ST. GEORGE MINING LIMITED
For more info SHARE ANALYSIS: TLX - TELIX PHARMACEUTICALS LIMITED
For more info SHARE ANALYSIS: TOR - TORQUE METALS LIMITED
For more info SHARE ANALYSIS: WBC - WESTPAC BANKING CORPORATION
For more info SHARE ANALYSIS: WC8 - WILDCAT RESOURCES LIMITED